Loading...
Loading...
MIRM| Name | Value |
|---|---|
| Revenues | 69.6M |
| Cost of Revenue | 22.6M |
| Gross Profit | 47.0M |
| Operating Expense | 77.0M |
| Operating I/L | -30.1M |
| Other Income/Expense | -2.8M |
| Interest Income | 3.8M |
| Pretax | -32.9M |
| Income Tax Expense | 0.2M |
| Net Income/Loss | -33.1M |
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for rare and orphan diseases. The company's primary focus is on LIVMARLI, an oral drug designed to treat progressive familial intrahepatic cholestasis disease, Alagille syndrome, and biliary atresia disease. Additionally, Mirum Pharmaceuticals is working on Volixibat, a drug targeting intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. These products form the core of the company's revenue stream, as it aims to address unmet medical needs in these specific disease areas.
